Cytological Samples: An Asset for the Diagnosis and Therapeutic Management of Patients with Lung Cancer

authors

• Frankel Diane
• Nanni Isabelle
• Ouafik L’houcine
• Greillier Laurent
• Dutau Hervé
• Astoul Philippe
• Daniel Laurent
• Kaspi Elise
• Roll Patrice

keywords

• Cytological sample
• Cytopathology
• Lung cancer
• Adenocarcinoma
• PD-L1
• Molecular testing
• NGS
• Immunocytochemistry

document type

abstract

Background: Lung cancer has become the leading cause of cancer death for men and women. Most patients are diagnosed at an advanced stage when surgery is no longer a therapeutic option. At this stage, cytological samples are often the less invasive source for diagnosis and the determination of predictive markers. We assessed the ability of cytological samples to perform diagnosis, and to establish molecular profile and PD-L1 expression, which are essential for the therapeutic management of patients. Methods: We included 259 cytological samples with suspected tumor cells and assessed the ability to confirm the type of malignancy by immunocytochemistry. We summarized results of molecular testing by next generation sequencing (NGS) and PD-L1 expression from these samples. Finally, we analyzed the impact of these results in the patient management. Results: Among the 259 cytological samples, 189 concerned lung cancers. Of these, immunocytochemistry confirmed the diagnosis in 95%. Molecular testing by NGS was obtained in 93% of lung adenocarcinomas and non-small cell lung cancer. PD-L1 results were obtained in 75% of patients tested. The results obtained with cytological samples led to a therapeutic decision in 87% of patients. Conclusion: Cytological samples are obtained by minimally invasive procedures and can provide enough material for the diagnosis and therapeutic management in lung cancer patients.

more information